Markoton (Heparin Sodium, Dexpanthenol)

Heparin sodium enhances the activity of antithrombin III, which in turn inhibits clotting factors IIa (thrombin) and Xa. This action reduces the formation of superficial clots while dexpanthenol supports skin regeneration.

The specific amount of Markoton to apply is determined by the prescribing healthcare professional based on the patient’s condition, treatment area, and clinical judgment. No standard dose is provided in public literature.

Safety data for topical heparin and dexpanthenol during pregnancy or lactation are limited. Use is advised only when clearly needed and after a risk‑benefit assessment by a qualified clinician.

To order Markoton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Markoton uniquely combines heparin sodium with dexpanthenol, offering both antithrombotic activity and skin‑repair benefits. Other topical heparin products may lack the added vitamin B5 derivative, potentially providing less support for barrier restoration and wound healing.

Store Markoton at room temperature below 25 °C. Keep the container tightly closed, protect it from moisture and direct sunlight, and retain it in the original packaging to maintain product stability.

Markoton is applied topically to the clean, dry skin area as directed by the prescriber. A thin layer is spread gently, avoiding excessive use or application to large surface areas unless specifically instructed.

Serious risks include severe allergic reactions such as anaphylaxis, extensive skin necrosis, and systemic bleeding if significant absorption occurs, especially when used together with other anticoagulant or antiplatelet therapies.

Markoton should be avoided in individuals with known hypersensitivity to heparin, dexpanthenol, or any formulation components, in patients with active bleeding disorders, and in those receiving systemic anticoagulant therapy unless specifically approved by a healthcare professional.